Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21670010 | 0.78 | ADORA1 (0.43) | ADORA1MAPTKDM4EESR2NR1H2 | |
| SCHEMBL6424372 | 0.78 | ADORA1 (0.53) | ADORA1MAPTKDM4EESR2NR1H2 | |
| SCHEMBL21638867 | 0.76 | DTYMK (0.44) | — | |
| SCHEMBL17377126 | 0.75 | ADORA1 (0.51) | ADORA1MAPTKDM4EESR2NR1H2 | |
| SCHEMBL17377058 | 0.75 | ADORA1 (0.51) | ADORA1MAPTKDM4EESR2NR1H2 | |
| SCHEMBL23790931 | 0.74 | ADORA1 (0.39) | ADORA1MAPTKDM4EESR2NR1H2 | |
| SCHEMBL31166059 | 0.73 | ADORA1 (0.61) | ADORA1MAPTKDM4EESR2NR1H2 | |
| SCHEMBL6425010 | 0.73 | ADORA1 (0.55) | ADORA1MAPTKDM4EESR2NR1H2 | |
| SCHEMBL17081077 | 0.73 | NR1H2 (0.44) | MAPTKDM4EESR2NR1H2MEN1 | |
| SCHEMBL21605391 | 0.73 | MAPT (0.60) | ADORA1MAPTKDM4EESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3830087-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2022-12-20 | — | — | US | disclosed |
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2021-09-09 | — | — | US | disclosed |
| WO-2020025587-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | NQO1, ALPI, LCT | ADORA1 3150/4885MAPT 4142/4885KDM4E 3565/4885 |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, ALPI, LCT | ADORA1 3150/4885MAPT 4142/4885KDM4E 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.